StreetInsider.com News Articles

Optimi Health completes psilocybin batch for trial and Australia supply

Wed, 23 Sep 2026 09:00:58 -0400

Optimi Health Corp. (NASDAQ: OPTH, CSE: OPTI) announced the completion and quality release of a production batch of 5mg naturally derived psilocybin capsules, manufactured at its cGMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence.

The batch will serve two purposes: supplying a Health Canada-authorized Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder (MDD), and fulfilling commercial orders from licensed clinics in Australia.

The Phase 2 trial is a multisite, open-label study of up to 200 participants, each receiving a single supervised dose. Patient dosing is expected to be completed by the end of 2027.

Optimi Health completes psilocybin batch for trial and Australia supply

Wed, 23 Sep 2026 09:00:58 -0400

The Phase 2 trial is a multisite, open-label study of up to 200 participants, each receiving a single supervised dose. Patient dosing is expected to be completed by the end of 2027.

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

Wed, 23 Sep 2026 09:00:00 -0400

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion and quality release of a production batch of 5mg naturally derived psilocybin capsules, manufactured end to end at the Company’s cGMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence. The batch will supply the recently announced Phase 2 clinical trial of psilocybin-assisted therapy evaluating psilocybin-assisted therapy in the treatment of major depressive disorder (“MDD”)

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

Wed, 23 Sep 2026 09:00:00 -0400

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

Wed, 23 Sep 2026 09:00:00 -0400

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

Wed, 23 Sep 2026 09:00:00 -0400

Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

Tue, 22 Sep 2026 09:00:00 -0400

VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the appointment of Michael Blough, Ph.D., as Chief Clinical Development Officer.

Dr. Blough has significant experience leading Health Canada-authorized clinical trials and has worked with Optimi on clinical trial applications since 2022. In this newly created position, he will oversee Optimi’s clinical development strategy and related operations. This includes the Company’s planned Phase 2 clinical trial evaluating naturally derived psilocybin-assisted psychotherapy to

Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

Tue, 22 Sep 2026 09:00:00 -0400

Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

Tue, 22 Sep 2026 09:00:00 -0400

Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

Tue, 22 Sep 2026 09:00:00 -0400

Optimi Health plans Phase 3 MDMA-assisted therapy trial for PTSD

Wed, 16 Sep 2026 08:25:15 -0400

Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) announced plans to initiate a Health Canada-authorized Phase 3 clinical trial evaluating MDMA-assisted therapy for post-traumatic stress disorder, with the trial expected to begin in 2027.

The trial is designed to enroll up to 100 participants across multiple sites in Canada. Enrollment will focus on veterans and current or former frontline workers, including military personnel, police, paramedics, firefighters, and healthcare workers.

Participants will receive the company's synthetic MDMA HCl in two dosage formats during two supervised sessions combined with psychotherapy, spaced several weeks apart. The primary efficacy endpoint will be change in the Clinician-Administered PTSD

Optimi Health plans Phase 3 MDMA-assisted therapy trial for PTSD

Wed, 16 Sep 2026 08:25:15 -0400

Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder

Wed, 16 Sep 2026 08:25:00 -0400

VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announces plans to initiate a Health Canada-authorized Phase 3 clinical trial evaluating MDMA (3,4-methylenedioxymethamphetamine)-assisted therapy for individuals with post-traumatic stress disorder ("PTSD"). The trial is expected to begin in 2027.

The Phase 3 clinical trial is intended to enroll up to 100 participants across multiple sites in Canada, with enrollment focused on veterans and current or former frontline workers, including military, police, paramedics, firefighters

Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder

Wed, 16 Sep 2026 08:25:00 -0400

Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder

Wed, 16 Sep 2026 08:25:00 -0400

Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder

Wed, 16 Sep 2026 08:25:00 -0400

Optimi Health to start Phase 2 psilocybin trial for depression

Thu, 10 Sep 2026 08:45:24 -0400

Optimi Health Corp. (Nasdaq: OPTH) announced plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder (MDD), according to a press release from the Vancouver-based company.

The trial, authorized by Health Canada, is planned to begin in the first half of 2027, with dosing expected to be completed by the end of 2027. Up to 200 participants will be enrolled across multiple sites in Canada, receiving a single supervised dose of naturally derived psilocybin. The primary efficacy endpoint is the change in Montgomery-Åsberg Depression Rating Scale total score from baseline.

Optimi states it will supply psilocybin

Optimi Health to start Phase 2 psilocybin trial for depression

Thu, 10 Sep 2026 08:45:24 -0400

Optimi states it will supply psilocybin

Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder

Thu, 10 Sep 2026 08:45:00 -0400

Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027

Up to 200 participants at sites across Canada, among the largest studies of naturally derived psilocybin to date

VANCOUVER, British Columbia, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (“Optimi” or the “Company”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announces plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with major depressive disorder ("MDD"). The trial is planned to

Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder

Thu, 10 Sep 2026 08:45:00 -0400

Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027

Up to 200 participants at sites across Canada, among the largest studies of naturally derived psilocybin to date

Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder

Thu, 10 Sep 2026 08:45:00 -0400

Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027

Up to 200 participants at sites across Canada, among the largest studies of naturally derived psilocybin to date

Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder

Thu, 10 Sep 2026 08:45:00 -0400

Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027

Up to 200 participants at sites across Canada, among the largest studies of naturally derived psilocybin to date

Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 08:30:00 -0400

VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (“Optimi” or the “Company”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held September 14-16, 2026, at the Lotte New York Palace Hotel.

A Company presentation will be available on demand here beginning Friday, September 11, 2026, at 7:00 a.m. ET. Management will be available for one-on-one meetings throughout the conference.

Investors interested

Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 08:30:00 -0400

A Company presentation will be available on demand here beginning Friday, September 11, 2026, at 7:00 a.m. ET. Management will be available for one-on-one meetings throughout the conference.

Investors interested

Optimi Health Establishes Discretionary Equity Facility

Fri, 14 Aug 2026 16:55:00 -0400

VANCOUVER, British Columbia, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the “Company” or “Optimi”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it has entered into a common shares purchase agreement (the “Purchase Agreement”) with Seven Knots, LLC (“Seven Knots”), establishing an equity line of credit (the “ELOC”) under which the Company has the right, but not the obligation, to sell to Seven Knots up to US$100 million of its common shares from time to time over the term of the facility.

Sales